Showing 221 - 240 results of 9,782 for search '"therapeutics"', query time: 0.06s Refine Results
  1. 221
  2. 222

    Digital therapeutics in Korea: current status, challenges, and future directions – a narrative review by Hee Jun Shin, Ik Tae Cho, Wan Suk Choi, Hong Rae Kim, Min Bong Kang, Won Jong Yang

    Published 2025-01-01
    “…Digital therapeutics (DTx) are emerging as a transformative innovation in healthcare offering evidence-based digital interventions for the treatment, management, and prevention of various diseases and disorders. …”
    Get full text
    Article
  3. 223

    A Canadian Working Group Report on Fecal Microbial Therapy: Microbial Ecosystems Therapeutics by Emma Allen-Vercoe, Gregor Reid, Norman Viner, Gregory B Gloor, Susy Hota, Peter Kim, Christine Lee, Kieran C O’Doherty, Stephen J Vanner, J Scott Weese, Elaine O Petrof

    Published 2012-01-01
    “…The report highlights the promise of fecal microbial therapy and related synthetic stool therapy (together called ‘microbial ecosystems therapeutics’) for the treatment of Clostridium difficile colitis and, possibly, other disorders. …”
    Get full text
    Article
  4. 224

    Design of a new class of broad-spectrum therapeutics targeted to drug-resistant bacteria by Amrutha Surendran, Agnes Turnbull, Allen Flockhart, Fern Findlay-Greene, Martyna Nowosielska, Donald Morrison, David J. Mincher, Samantha Donnellan

    Published 2024-12-01
    “…We hypothesise that antimicrobial resistance (AMR) cannot be overcome by simply ‘drugging’ single biological targets, therefore, our focus is developing broad-spectrum therapeutics. Herein we present the synthesis of two novel spacer-linked, anthraquinone-triphenylphosphonium (AQ-TPP) conjugates (4) and (5) as early lead compounds in a new class of agent designed to penetrate the lipophilic barriers of the membranes of a diverse family of species; and establish bacterial growth inhibitory properties against methicillin-resistant Staphylococcus aureus (NCTC 13616) and Mycobacterium smegmatis [mc2155] (as a surrogate for Mycobacterium tuberculosis). …”
    Get full text
    Article
  5. 225

    Synthesis and evaluation of nitrochromene derivatives as potential antileishmanial therapeutics through biological and computational studies by Niloofar Javid, Ali Asadipour, Ehsan Salarkia, Mohammad Amin Langarizadeh, Fatemeh Sharifi, Mohammad Mahdavi, Bagher Amirheidari, Aida Iraji, Hojjat Rezaiezadeh, Gholamreza Hassanpour, Yaghoub Pourshojaei

    Published 2025-01-01
    “…In light of these limitations, developing new therapeutic agents that can effectively disrupt the parasite’s life cycle at multiple stages is of paramount importance. …”
    Get full text
    Article
  6. 226
  7. 227
  8. 228
  9. 229
  10. 230
  11. 231
  12. 232

    CLOVES Syndrome: A Review of Clinical, Genetic, and Therapeutic Aspects by Julianna Podolec, Silvia Ciraolo, Joanna Wojda, Adam Sobiński, Zuzanna Kościuszko, Katarzyna Kurza, Agnieszka Kulczycka-Rowicka, Matylda Czerwonka, Katarzyna Lesiczka-Fedoryj, Anna Walczak

    Published 2025-02-01
    “…The primary materials used in the research include: clinical case reports and studies, imaging studies, genetic analysis, therapeutic interventions, epidemiological data, literature review and data analysis. …”
    Get full text
    Article
  13. 233

    Ferroptosis Is a Potential Therapeutic Target for Pulmonary Infectious Diseases by Yurong Zhang, Dianlun Qian, Xiangfeng Bai, Shibo Sun

    Published 2023-01-01
    “…Ferroptosis may be a potential therapeutic target for pulmonary infectious diseases. …”
    Get full text
    Article
  14. 234
  15. 235

    PPARγ as a Novel Therapeutic Target in Lung Cancer by Aravind T. Reddy, Sowmya P. Lakshmi, Raju C. Reddy

    Published 2016-01-01
    “…This review of the current literature highlights the potential of PPARγ agonists as novel therapeutic modalities in lung cancer, either as monotherapy or in combination with standard cytotoxic chemotherapy.…”
    Get full text
    Article
  16. 236
  17. 237
  18. 238
  19. 239

    Nanobody engineering: computational modelling and design for biomedical and therapeutic applications by Nehad S. El Salamouni, Jordan H. Cater, Lisanne M. Spenkelink, Haibo Yu

    Published 2025-02-01
    “…This review further underscores the advantages of nanobodies over conventional antibodies from a biosynthesis perspective, including their small size, stability, and solubility, which make them ideal candidates for economical antigen capture in diagnostics, therapeutics, and biosensing. We discuss the recent advancements in computational methods for nanobody modelling, epitope prediction, and affinity maturation, shedding light on their intricate antigen‐binding mechanisms and conformational dynamics. …”
    Get full text
    Article
  20. 240